Biotech Stock Collapses After Failed Drug Study

Short sellers have been flocking to VBLT in recent weeks

Managing Editor
Mar 8, 2018 at 9:59 AM
facebook twitter linkedin

Vascular Biogenics Ltd (NASDAQ:VBLT) is the worst stock on the Nasdaq today, down 65% to trade at $2.38 -- and just off a new record low of $2.30 -- after the biotech's brain cancer drug failed to meet its late-stage study goals. However, the company said it believes VB-111 "may still hold promise for other indications we currently or may study in the future."

Prior to today's freefall, VBLT stock had tacked on 19% year-over-year, and had found support at its 200-day moving average, after pulling back from a two-year high of $9.05 on Nov. 16. Now, however, the security is on track for its worst single-day performance of all time. 

Although the stock is currently short-sale restricted, plenty of short sellers are likely cheering today's collapse. Short interest increased by nearly 60% during the last two reporting periods, and now represents 6.7% of VBLT's total available float.

Analysts could re-think their bullish positions on the tanking drug name. The three brokerage firms tracking VBLT rate it a "strong buy," while the stock's average 12-month price-target of $14.75 represents a 520% premium to its current perch. Should VBLT continue to languish, it could prompt downgrades and/or price-target cuts. 


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!